Immunisation schedule of the Pediatric Spanish Association: 2024 recommendations by Francisco José Álvarez García, Antonio Iofrío de Arce, Javier Álvarez Aldeán, Elisa Garrote Llanos, Lucía López Granados, María Luisa Navarro Gómez, Valentín Pineda Solas, Irene Rivero Calle, Jesús Ruiz-Contreras, Ignacio Salamanca de la Cueva, Pepe Serrano Marchuet, Francisco José Álvarez García, Antonio Iofrío de Arce, Javier Álvarez Aldeán, María Garcés-Sánchez, Elisa Garrote Llanos, Abián Montesdeoca Melián, María Luisa Navarro Gómez, Valentín Pineda Solas, Irene Rivero Calle, Jesús Ruiz-Contreras, Pepe Serrano Marchuet

“…The AEP 2025 Vaccination and Immunization Schedule recommended for children, adolescents and pregnant women residing in Spain features the following novelties:Due to the increase in measles cases and outbreaks in recent years, we recommend advancing the second dose of measles, mumps and rubella (MMR) vaccine to 2 years of age.As a consequence of the above, since many autonomous communities (ACs) use the quadrivalent vaccine for the second dose of MMR and varicella vaccines, we recommend, for all ACs, advancing the second dose of varicella vaccine to 2 years of age.Due to the very significant increase in cases of pertussis since late 2023 and especially in 2024, we recommend advancing the dose of Tdap given in adolescence to 10–12 years of age.To complete protection against meningococcal disease in adolescence, we recommend vaccination against MenB at age 12 years.We believe that vaccination against seasonal influenza should be routine up to age 18 years, but given the disappointing coverage in children aged 6–59 months, we currently consider that improving this coverage should be prioritised, extending vaccination to children and adolescents aged 5–18 years once this objective has been achieved.Among other aspects, the routine immunization tables for healthy individuals and risk groups, the use of the new extended-valence conjugate vaccines against pneumococcal disease, routine vaccination at 4 months of age with MenACWY and vaccination against SARS-CoV-2 for individuals aged more than 6 months with risk factors remain unchanged with respect to the 2024 schedule. …”
Get full text

Omicron: The rising fear for another wave in Malaysia by Lydia Ngiik-Shiew Law, Ke-Yan Loo, Joanna Xuan Hui Goh, Priyia Pusparajah

“…Pharmaceutical companies raced against the time to develop vaccines, believing that it would be sufficient to control COVID-19. …”
Get full text

Diagnosis and Management of Bacterial Meningitis in the Paediatric Population: A Review by Catherine L. Tacon, Oliver Flower

“…Over recent decades new vaccines have led to a change in epidemiology of the disease; however, it remains a condition that requires a high index of suspicion, prompt diagnosis, and early management in the emergency department. …”
Get full text

EDITORIAL PAPER - MEDICAL TECHNIQUES by JT ADMIN

“…Health technology research could be in the form of procedures, vaccines, devices and systems as outlined by the world health organization in its Health technology assessment report. …”
Get full text

The Involvement of Microglial Cells in Japanese Encephalitis Infections by Thananya Thongtan, Chutima Thepparit, Duncan R. Smith

“…Despite the availability of effective vaccines, Japanese encephalitis virus (JEV) infections remain a leading cause of encephalitis in many Asian countries. …”
Get full text

Tailored Therapy in Lung Cancer by George Rakovich, Lise Tremblay

“…In addition, other related areas of active investigation, including tumour vaccines and pharmacogenetics, are briefly reviewed.…”
Get full text

Evaluation of IgG binding capability to SARS-CoV-2 variants in early COVID-19 convalescent sera using an indirect ELISA by Behzad Hussain, Peizhe Zhao, Yu Liu, Bo Yang, Xiaoxiong Li, Zhichao Zhang, Guoqiang Feng, Demei Zhang, Defen Lu, Wu Changxin

“…These results indicate that the patients recovering from natural infection of early original Wuhan strain may have the potential to resist infection of current circulating variants and the vaccines using the prototype antigen may still work for newly emerged variants.…”
Get full text

The Mycoplasma hyopneumoniae protein Mhp274 elicits mucosal and systemic immune responses in mice by Mengqi Xie, Zhongshun Huang, Yun Zhang, Yujie Gan, Huiying Li, Dan Li, Honglei Ding

“…The bottleneck in the development of more effective vaccines for MPS is the stimulation of effective immune responses in the host. …”
Get full text

A diagnostic host-specific transcriptome response for Mycoplasma pneumoniae pneumonia to guide pediatric patient treatment by Sandra Viz-Lasheras, Alberto Gómez-Carballa, Xabier Bello, Irene Rivero-Calle, Ana Isabel Dacosta, Myrsini Kaforou, Dominic Habgood-Coote, Aubrey J. Cunnington, Marieke Emonts, Jethro A. Herberg, Victoria J. Wright, Enitan D. Carrol, Stephane C. Paulus, Werner Zenz, Daniela S. Kohlfürst, Nina Schweintzger, Michiel Van der Flier, Ronald de Groot, Luregn J. Schlapbach, Philipp Agyeman, Andrew J. Pollard, Colin Fink, Taco T. Kuijpers, Suzanne Anderson, Ulrich Von Both, Marko Pokorn, Dace Zavadska, María Tsolia, Henriëtte A. Moll, Clementien Vermont, Michael Levin, Federico Martinón-Torres, Antonio Salas, On behalf of EUCLIDS, PERFORM, and DIAMONDS consortia

Get full text

Transgenic Killer Commensal Bacteria as Mucosal Protectants by Luciano Polonelli

“…Unfortunately, current strategies for mucosal protection against candidiasis are severely limited by the lack of effective vaccines and the relative paucity and toxicity of commercially available antifungal drugs. …”
Get full text

The mental health implication of mpox: Enhancing care with genetic insights by Ovinuchi Ejiohuo

“…Furthermore, genetic insights can inform the development of safer vaccines and early interventions, particularly for vulnerable populations. …”
Get full text

Technological Cooperation Networks at Bio-Manguinhos: the Role of Information and Communication Technologies by Lázaro Pereira de Oliveira, Claudio Pitassi, Antônio Augusto Gonçalves

“…This article identifies and discusses the contribution of information and communication technologies (ICTs) to the technological cooperation projects of Bio-Manguinhos, a pharmaceutical manufacturer that belongs to Osvaldo Cruz Foundation (FIOCRUZ), responsible for producing vaccines, reagents and biopharmaceuticals, with priority on meeting the needs of the Brazilian public health system. …”
Get full text

Structural Predestination of Individual Diversity in the Course and Severity of Infectious Diseases by Sergey N. Rumyantsev

Get full text

Streptococcal Infections of Fish by Roy Yanong, Ruth Francis-Floyd

“…Preventive measures emphasize maintaining optimal water quality, minimizing stress, and employing vaccines and immunostimulants. Additionally, the document addresses the zoonotic potential of Streptococcus iniae, highlighting the low risk to healthy individuals but cautioning immunocompromised persons. …”
Get full text

Streptococcal Infections of Fish by Roy Yanong, Ruth Francis-Floyd

“…Preventive measures emphasize maintaining optimal water quality, minimizing stress, and employing vaccines and immunostimulants. Additionally, the document addresses the zoonotic potential of Streptococcus iniae, highlighting the low risk to healthy individuals but cautioning immunocompromised persons. …”
Get full text

The Role of Pneumococcal Virulence Factors in Ocular Infectious Diseases by Angela H. Benton, Mary E. Marquart

“…Though two pneumococcal vaccines exist for the prevention of nonocular diseases, they do little to fully prevent ocular infections. …”
Get full text

Incidence of acute lower respiratory tract disease hospitalisations, including pneumonia, among adults in Bristol, UK, 2019, estimated using both a prospective and retrospective me... by Jo Southern, Adam Finn, Catherine Hyams, James Campling, Bradford D Gessner, Elizabeth Begier, Maria Garcia Gonzalez, Sharon Gray, Jennifer Oliver

“…This may have significant consequences for healthcare planning, including usage of current and future vaccinations against respiratory infection.…”
Get full text

Research Note: Establishment of vector system harboring duck RNA polymerase I promoter for avian influenza virus by Yunyueng Jang, Yoon-Gi Baek, Yu-Na Lee, Ra Mi Cha, Yun-Chan Choi, Min-Ji Park, Youn-Jeong Lee, Eun-Kyoung Lee

“…Reverse genetics (RG) systems are extensively utilized to investigate the characteristics of influenza viruses and develop vaccines, predominantly relying on human RNA polymerase I (pol I). …”
Get full text

Human adenovirus species B knob proteins as immunogens for inducing cross-neutralizing antibody responses by Zhenwei Liu, Yuting Xian, Jixian Lan, Zhichao Zhou, Xiao Li, Rong Zhou, Dehui Chen, Xingui Tian

“…Therefore, the development of multivalent vaccines against HAdV types 3, 7, 14, and 55 remains an important goal. …”
Get full text